Startseite>>Signaling Pathways>> Others>>DBCO-PEG4-Biotin

DBCO-PEG4-Biotin

Katalog-Nr.GC61573

DBCO-PEG4-Biotin ist ein Azadibenzocyclooctin-Biotin-Derivat, das eine Biotin-Gruppe und 4 PEGs enthÄlt. DBCO-PEG4-Biotin ist ein vielseitiges Biotinylierungsreagenz, das fÜr die EinfÜhrung einer Biotineinheit in Azid-markierte BiomolekÜle Über eine kupferfreie stammgefÖrderte Alkin-Azid-Click-Chemie (SPAAC)-Reaktion verwendet wird.

Products are for research use only. Not for human use. We do not sell to patients.

DBCO-PEG4-Biotin Chemische Struktur

Cas No.: 1255942-07-4

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
218,00 $
Auf Lager
5mg
132,00 $
Auf Lager
10mg
178,00 $
Auf Lager
25mg
285,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

DBCO-PEG4-Biotin is an azadibenzocyclooctyne-biotin derivative containing a biotin group and 4 PEGs. DBCO-PEG4-Biotin is a versatile biotinylation reagent used for the introduction of a biotin moiety to azide-labeled biomolecules via copper-free strain-promoted alkyne-azide click chemistry (SPAAC) reaction[1].

The alkyne group can react with azide moiety in copper-free Click Chemistry reaction to form a stable triazole linkage.

[1]. Hammink R, et al. Affinity-Based Purification of Polyisocyanopeptide Bioconjugates. Bioconjug Chem. 2017 Oct 18;28(10):2560-2568.

Bewertungen

Review for DBCO-PEG4-Biotin

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DBCO-PEG4-Biotin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.